Phase 2 N=56 Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF)
Anemia
Primary: Change in Left Ventricular End-diastolic Volume — -6; -4 mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=100 Practical Anemia Bundle for SusTained Blood Recovery
Anemia · Critical Illness
Primary: Hemoglobin Concentrations — 11.5; 12.2 g/dL — p=0.02
N/A N=62 Intelligent Control Approach to Anemia Management
End-Stage Renal Disease
Primary: Percent Hb 10-12 g/dL — 61.9; 72.5 Percent
N/A N=809 Is Iron Deficiency the Cause of Anemia Among Women in Cambodia?
Anemia · Iron Deficiency · Hemoglobin Disorder
Primary: Hemoglobin Levels at 12-weeks. Marginal Means (95% CI). — 123; 116; 121; 116 g/L — p=<0.05
Phase 3 N=402 Sub-clinical Inflammation and Iron Supplementation
Anemia
Primary: Haemoglobin Level — 88.3; 89.2; 88.4; 89.6 g/L — p=<0.05
N/A N=146 Analyses of Anemia in Very Low Birth Weight (VLBW) Infants.
Very Preterm Maturity of Infant · The Risk Factors for Improving the Prognosis of VLBW Infants
Primary: The Incidence of Early Onset Sepsis in VLBW Infants With AOP. — 18; 34; 7; 42 Participants
N/A N=102 Iron Parameters in Non-anemic First Trimester Gravidas
Iron Deficiency (Without Anemia) · Pregnancy
Primary: Percent of Non-anemic Patients With Iron Deficiency Stratified by Gravidity — 9; 3; 6; 38 Participants
Phase 3 N=51 Daily vs. Every Other Day Oral Iron Supplementation in Patients With Absolute Iron Deficiency Anemia
Anemia · Iron Deficiency Anemia
Primary: Feasibility of Enrolling Patients in the Trial — 85 participants
Phase 3 N=594 Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis
Anemia in Chronic Kidney Disease in Non-dialysis Patients
Primary: Percentage of Participants With a Hemoglobin (Hb) Response to Treatment at Two Consecutive Visits During the First 24 Weeks of Treatment Without Rescue Therapy Prior to…
N/A N=441 Anemia Management in Chronic Kidney Disease Not on Dialysis Patients After the European Renal Best Practice (ERBP) Working Group Recommendations
ANEMIA
Primary: % Patients Achieving Target Hemoglobin Levels — 42.5; 35.3 percentage of participants
N/A N=851 Association of Anemia With Hospital Costs in Elective Colorectal Surgery
Surgery · Surgical Blood Loss · Anemia
Primary: Total Hospital Costs — 23,667; 17,100 Dollars
Phase 3 N=40 Heme Iron Polypeptide for Iron Deficiency Anemia in Chronic Renal Failure
Anemia · Renal Failure
Primary: Hemoglobin Concentration at 6 Months — 117; 113 g/L
Phase 3 N=2,018 Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients
Anemia
Primary: Evaluate the Safety of the Maximum Administered Dose, 15 mg/kg (up to a Maximum 1,000 mg) of FCM Compared to SMC. — 6; 22 participants
Phase 4 N=38 Intravenous Iron for Iron-deficiency Anemia in Pregnancy: a Randomized Controlled Trial
Iron Deficiency Anemia of Pregnancy · Iron Malabsorption
Primary: Maternal Anemia at Delivery — 4; 11 Participants — p=0.039
Phase 2 N=74 Intravaneous Iron(1000 mg Low Molecular Weight Iron Dextran Over 60 Minutes) for Pregnant Women
Pregnancy
Primary: Percentage of Women Who Achieve Anemia Correction After a Single Dose of 1000mg of Low Molecular Weight Iron Dextran(INfeD). — 35; 11 Participants
Phase 4 N=154 Clinical Evaluation of Iron Treatment Efficiency Among Non-anemic But Iron-deficient Female Blood Donors
Fatigue · Iron Deficiency
Primary: Level of Fatigue Before and After Iron Treatment/Placebo, Using a 10 Point Visual Analogue Scale. — 3.4; 3.5 centimeter — p=0.69
N/A N=112 Sickle Cell Anemia WE CARE
Sickle Cell Disease
Primary: Number of Emergency Department (ED)/Acute Care Visits — 0; 1 number of visits
Phase 4 N=184 Treatment Response in Dialysis Anaemia
Anaemia · Haemodialysis
Primary: Haemoglobin Increase of Greater or Equal to 5g/l Following Receipt of Treatment — 53; 61 Participants
Phase 2 N=15 Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)
Anaemia
Primary: Percentage of Fractional Oral Iron Absorption Following Treatment With Daprodustat and rhEPO — 20.64; 20.62 Percentage (%) of iron absorbed — p=0.9971
Phase 3 N=703 Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency Anemia
Anemia
Primary: Safety, as Defined by the Occurence of Serious Adverse Events (SAE's), of FCM Compared to SMC — 17; 11 participants
Phase 3 N=170 (ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy
Anemia
Primary: Change From Baseline in Left Ventricle Mass Index (LVMI) at Month 15 — 0.69; 0.10 g/m^2 — p=0.8811
N/A N=132 Impact of Vitamin B12 Replacement on Epogen Dosing and Improvement of Quality of Life in Hemodialysis Patients
Vitamin B12 Deficiency
Primary: Change in Amount of Epogen Required — -16,572 unit/ml
Phase 3 N=270 A Study to Demonstrate the Efficacy and Tolerability of Ferrous Bisglycinate Chelate in Iron Deficiency Anaemia and to Compare These With Those of Ferrous Ascorbate.
Haematopoiesis
Primary: Change From Baseline in Hemoglobin (Hb) After 8 Weeks of Treatment in Each Ferrous Bisglycinate Chelate Group (1 Tablet Daily and 2 Tablets Daily) — 2.6; 2.8 Gram per…
Phase 3 N=160 Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Iron Dextran in Treating Iron Deficiency Anemia
Anemia
Primary: The Number of Subjects Who Reported Treatment-emergent Adverse Events (AE's) — 60; 59 participants
Phase 3 N=312 Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)
Anaemia
Primary: Mean Change From Baseline in Hemoglobin (Hgb) During Evaluation Period (Week 28 to Week 52) — 1.02; 1.12 Grams per deciliter
N/A N=150 IV Iron for the Anemia of Traumatic Critical Illness
Trauma · ICU Anemia
Primary: RBC Transfusion — 47; 55 participants
Phase 2 N=22 Efficacy and Safety of Peginesatide (AF37702) in the Treatment of Anemia in Participants With Chronic Kidney Disease
Anemia · Chronic Kidney Disease · Chronic Renal Failure
Primary: Percentage of Participants Who Experienced Increase and Maintain Hemoglobin Levels (Two Consecutive Values) Greater Than or Equal to the Lower Limit of the Target Range…
N/A N=22 Does a Daily Iron Tablet Improve Anemia in Cystic Fibrosis
Cystic Fibrosis · Anemia, Iron-Deficiency
Primary: Change From Baseline in Hemoglobin Concentration (gm/dl) — 0.12; 0.09 gm/dl — p=0.81
Phase 1 N=33 A Phase 1 Study of LY2787106 in Cancer and Anemia
Anemia
Primary: Number of Participants With Clinically Significant Events — 4; 3; 6; 5 participants
Phase 3 N=2,964 Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)
Anaemia · Aspergillosis, Allergic Bronchopulmonary
Primary: Time to First Occurrence of Adjudicated Major Adverse Cardiovascular Event (MACE) During Cardiovascular (CV) Events Follow-up Time Period: Non-inferiority Analysis…